Quantum Cyber N.V. annual report, Q4 FY2023

Filing summary

Identity and period: The supplied filing is Mainz Biomed N.V.’s Form 20-F annual report for the fiscal year ended December 31, 2023, filed April 8, 2024. It is not a filing for Quantum Cyber N.V.; investors should confirm that this is the intended issuer. The company’s Nasdaq ticker is MYNZ. Financial statements are prepared under IFRS as issued by the IASB. The filing reports annual results, not a standalone 2023 Q4 period.

Business context and reporting period

Mainz Biomed develops and sells in-vitro diagnostic tests for early cancer detection. Its marketed product, ColoAlert, is a colorectal cancer screening test sold in European markets, primarily Germany. The company also operates a diagnostic laboratory and is developing a next-generation colorectal screening test and PancAlert, an early-stage pancreatic cancer test.

Financial performance and position

MetricFY 2023FY 2022
Revenue$895,479$529,877
Gross profit / margin$509,659 / 57%$182,151 / 34%
Operating expenses$27.15 million$26.63 million
Operating loss$26.64 million$26.44 million
Net loss$26.30 million$26.39 million
Comprehensive loss$26.80 million$26.34 million
Basic and diluted loss per share$1.62$1.86
Cash used in operating activities$21.94 million$14.77 million
Cash at year-end$7.07 million$17.14 million
  • Revenue increased 69%, mainly from greater ColoAlert sales, primarily in Germany. Gross margin improved to 57%; management attributed the improvement to a greater contribution from testing performed in its own laboratory.
  • Research and development expense rose 91% to $9.59 million, principally reflecting higher staffing and costs for the ColoFuture and eAArly DETECT studies. Sales and marketing expense declined 4% to $6.16 million; general and administrative expense declined 25% to $11.41 million, mainly due to lower stock-option expense.
  • At December 31, 2023, total assets were $15.41 million, total liabilities $12.16 million, and shareholders’ equity $3.25 million. Current assets of $8.98 million were below current liabilities of $9.24 million.
  • Liabilities included $4.86 million carrying value for the principal convertible promissory notes, $1.03 million of silent partnerships, $1.45 million of lease liabilities, and $1.12 million remaining ColoAlert intellectual-property acquisition payments. The promissory notes had $6.4 million face value outstanding at year-end; the carrying value differs because the notes were measured at fair value.
  • Weighted-average shares outstanding increased 15% to 16.24 million. The company reported 21,165,482 ordinary shares outstanding at year-end.

Material changes, outlook, and risks

  • Going concern and financing: The company had an accumulated deficit of $69.33 million and recurring operating losses and cash outflows. Management and the auditor concluded that substantial doubt exists about the company’s ability to continue as a going concern for one year from the financial-statement issuance date. Management expects cash on hand, planned financing, and possible cost deferrals to fund at least that period, but future financing is uncertain and may dilute shareholders or be unavailable on acceptable terms.
  • Convertible-note default: The Pre-Paid Advance Agreement notes had a trigger event and default in November 2023. The company disclosed 15% default interest and required monthly cash payments, alongside an 8% redemption premium under specified terms. From January 1 to March 26, 2024, it paid $858,415 in cash and issued 721,093 shares, reducing outstanding principal by $1,246,449; a March 27 payment was deferred by mutual agreement into April while payment amount and timing were discussed.
  • Product and regulatory outlook: Management plans to pursue FDA authorization for ColoAlert, including a planned pivotal study, reconAAsense, expected to involve approximately 15,000 participants at 150 U.S. sites. The filing does not provide firm revenue or profitability guidance. FDA approval, study outcomes, timing, funding, market acceptance, reimbursement, and competition remain material uncertainties. The company is also working toward compliance for its ColoAlert PCR kit under EU IVDR requirements.
  • Clinical results: The company reported topline eAArly DETECT results in December 2023 from 254 evaluable U.S. subjects: 97% sensitivity for colorectal cancer, 97% specificity, and 82% sensitivity for advanced adenoma. ColoFuture results reported 94% sensitivity and 97% specificity for colorectal cancer and 80% sensitivity for advanced adenoma. These are study results, not FDA authorization or proof of commercial performance.
  • Other notable items: In February 2023, Mainz acquired ColoAlert intellectual property for cash, restricted shares, and a capped per-test revenue share, replacing the prior profit-split arrangement. It also acquired UdeS biomarkers subject to a 2% net-sales profit share on products using them. One customer accounted for 21% of 2023 revenue, versus two customers accounting for 38% in 2022. The company reported no material litigation and assessed disclosure controls and internal control over financial reporting as effective; the auditor did not attest to internal-control effectiveness.
  • Other significant risks include dependence on ColoAlert, physician and patient adoption, limited reimbursement, competition, product performance and liability, protection of intellectual property, foreign-exchange exposure, and potential dilution. The company does not expect to pay dividends in the foreseeable future.

Important facts for investors to verify

  1. Confirm the intended issuer: this is a Mainz Biomed N.V. filing, not a Quantum Cyber N.V. filing.
  2. Review the going-concern note, cash runway assumptions, subsequent financing, and whether the company met its note-payment obligations after the reported deferral.
  3. Check current outstanding shares, warrants, options, and convertible securities for dilution; the year-end share count and later share issuances differ.
  4. Verify the status, enrollment, endpoints, timing, and regulatory pathway of reconAAsense and the EU IVDR compliance process.
  5. Assess whether clinical-study findings translate into independently validated test performance, physician adoption, reimbursement, and recurring revenue.
  6. Reconcile the note’s reported debt face values, fair-value carrying amounts, conversion terms, and post-year-end repayments using subsequent SEC filings.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.